The medical technology firm reported Q4 revenue growth and issued a fiscal 2027 outlook as Persona PLUS and IVT initiatives progress.
Haemonetics reported fourth-quarter revenue of $346 million, a 5% increase year-over-year, with organic growth excluding CSL reaching 9%. Adjusted earnings per share rose 4% to $1.29.
The company’s guidance for fiscal 2027 projects revenue growth of 4% to 7%, driven by the rollout of its Persona PLUS system and efforts to rebound in the IVT segment. Prior-year revenue growth was 6% on a reported basis.
Management attributed the results to strong demand in plasma and hospital businesses, though macroeconomic pressures remain a consideration.